OncoMatch/Clinical Trials/NCT05483400
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
Is NCT05483400 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tiragolumab and atezolizumab for head and neck neoplasms.
Treatment: Tiragolumab and atezolizumab — In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Melanoma
Biomarker criteria
Required: PD-L1 (CD274) expression (CD8 imaging substudy participation required if slots available)
Participate in the GE-269-001 CD8 investigational imaging trial provided that there are slots is that trial.
Disease stage
Required: Stage CLINICAL T2-4A, NODE POSITIVE
clinical T2-4a, or node positive resectable HPV-unrelated HNSCC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor (anti-PD1, anti-PD-L1)
Exception: only for cohort 1, 2 and 4
Prior immune checkpoint inhibitor treatment, including but not limited to anti-PD1 and anti-PD-L1 antibodies (only for cohort 1, 2 and 4)
Lab requirements
Blood counts
hemoglobin ≥9.0 g/dL; platelet count ≥100 x 10^9
Kidney function
serum creatinine ≤1.5 x ULN or estimated GFR > 30 mL/min/1.73 m2; 24-hour urine creatinine collection may substitute
Liver function
total bilirubin ≤1.5 x ULN (≤3 x ULN if liver tumor involvement); AST ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALT ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALP ≤2.5 x ULN (≤5 x ULN if liver or bone tumor involvement); Gilbert's syndrome exception
Adequate organ and bone marrow function defined as: hemoglobin ≥9.0 g/dL; platelet count ≥100 x 10^9; serum creatinine ≤1.5 x ULN or estimated GFR > 30 mL/min/1.73 m2. Adequate hepatic function defined as: total bilirubin ≤1.5 x ULN (≤3 x ULN if liver tumor involvement); AST ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALT ≤2.5 x ULN (≤5 x ULN if liver tumor involvement); ALP ≤2.5 x ULN (≤5 x ULN if liver or bone tumor involvement). Gilbert's syndrome exception.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify